Perindopril
Generic name
Perindopril
Brand name
ATC Code
C09AA04
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No studies have been conducted on pharmacokinetic parameters in children.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Prophylaxis and treatment of cardiomyopathy in boys with Duchenne Muscular Dystrophy | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
Renal impaiment in children > 3 months
Perindopril base:
- creatinine clearance 30-50 ml/min: no dose adjustments required.
- creatinine clearance 10-30 ml/min: max. 1.7 mg/day in 1 dose, every 2 days or according to effect up to the highest possible tolerated dose (protective effect on renal function)
This equals:
-
- ‘tertbutylamine’ (= ‘erbumine’): max. 2 mg/day, in 1 dose, every 2 days or according to effect up to the highest possible tolerated dose (protective effect on renal function)
- ‘arginine’: max. 2.5 mg/day in 1 dose, every 2 days or up to the highest tolerated dose according to effect (protective effect on renal function).
- ‘tosilate’: max. 2.5 mg/day in 1 dose, every 2 days or up to the highest tolerated dose according to effect (protective effect on renal function).
Clinical consequences
ACE inhibitors decrease intraglomerular filtration pressure and reduce proteinuria. As a result, they probably have a long-term protective effect on kidney function. For this reason, the highest possible dose is also given according to tolerance.
Creatinine and potassium concentrations should be monitored within 2 weeks of starting treatment and then at least once a year, depending on the patient's clinical condition
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
No specific side effects in children have been described in the literature.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Different products may contain different salts of perindopril.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ACE INHIBITORS, PLAIN
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| ACE inhibitors, plain | ||
|---|---|---|
| C09AA07 | ||
| C09AA01 | ||
| C09AA02 | ||
| C09AA03 | ||
| C09AA05 | ||
References
- Bourke JP, et al, Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy., Cochrane Database Syst Rev, 2018, 10(10), Cd009068.
- Bourke JP, et al., Preventing Cardiomyopathy in DMD: A Randomized Placebo-Controlled Drug Trial., Neurol Clin Pract., 2021, 11(5), e661-e8
- Duboc D, et al. 2005;, Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy., J Am Coll Cardiol., 2005, 45(6), 855-7
- Duboc D, et al., Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up., Am Heart J, 2007, 154(3), 596-602
Changes
Therapeutic Drug Monitoring
Overdose
